PURPOSE: This guideline is structured to provide a clinical framework stratified by cancer severity to facilitate care decisions and guide the specifics of implementing the selected management options. The summary presented herein represents Part II of the two-part series dedicated to Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline discussing risk stratification and care options by cancer severity. Please refer to Part I for discussion of specific care options and outcome expectations and management. MATERIALS AND METHODS: The systematic review utilized in the creation of this guideline was completed by the Agency for Healthcare Research and Quality and through additional supplementation by ECRI Institute. This review included articles published between January 2007 and March 2014 with an update search conducted through August 2016. When sufficient evidence existed, the body of evidence for a particular treatment was assigned a strength rating of A (high), B (moderate), or C (low) for support of Strong, Moderate, or Conditional Recommendations. Additional information is provided as Clinical Principles and Expert Opinions (table 2 in supplementary unabridged guideline, http://jurology.com/). RESULTS: The AUA (American Urological Association), ASTRO, and SUO (Society of Urologic Oncology) formulated an evidence-based guideline based on a risk stratified clinical framework for the management of localized prostate cancer. CONCLUSIONS: This guideline attempts to improve a clinician's ability to treat patients diagnosed with localized prostate cancer, but higher quality evidence in future trials will be essential to improve the level of care for these patients. In all cases, patient preferences should be considered when choosing a management strategy.
PURPOSE: This guideline is structured to provide a clinical framework stratified by cancer severity to facilitate care decisions and guide the specifics of implementing the selected management options. The summary presented herein represents Part II of the two-part series dedicated to Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline discussing risk stratification and care options by cancer severity. Please refer to Part I for discussion of specific care options and outcome expectations and management. MATERIALS AND METHODS: The systematic review utilized in the creation of this guideline was completed by the Agency for Healthcare Research and Quality and through additional supplementation by ECRI Institute. This review included articles published between January 2007 and March 2014 with an update search conducted through August 2016. When sufficient evidence existed, the body of evidence for a particular treatment was assigned a strength rating of A (high), B (moderate), or C (low) for support of Strong, Moderate, or Conditional Recommendations. Additional information is provided as Clinical Principles and Expert Opinions (table 2 in supplementary unabridged guideline, http://jurology.com/). RESULTS: The AUA (American Urological Association), ASTRO, and SUO (Society of Urologic Oncology) formulated an evidence-based guideline based on a risk stratified clinical framework for the management of localized prostate cancer. CONCLUSIONS: This guideline attempts to improve a clinician's ability to treat patients diagnosed with localized prostate cancer, but higher quality evidence in future trials will be essential to improve the level of care for these patients. In all cases, patient preferences should be considered when choosing a management strategy.
Authors: Kareem N Rayn; Jonathan B Bloom; Samuel A Gold; Graham R Hale; Joseph A Baiocco; Sherif Mehralivand; Marcin Czarniecki; Vikram K Sabarwal; Vladimir Valera; Bradford J Wood; Maria J Merino; Peter Choyke; Baris Turkbey; Peter A Pinto Journal: J Urol Date: 2018-05-29 Impact factor: 7.450
Authors: Vinay Prabhu; Andrew B Rosenkrantz; Ricardo Otazo; Daniel K Sodickson; Stella K Kang Journal: J Magn Reson Imaging Date: 2019-01-10 Impact factor: 4.813
Authors: Jeremie Calais; Amar U Kishan; Minsong Cao; Wolfgang P Fendler; Matthias Eiber; Ken Herrmann; Francesco Ceci; Robert E Reiter; Matthew B Rettig; John V Hegde; Narek Shaverdian; Chris R King; Michael L Steinberg; Johannes Czernin; Nicholas G Nickols Journal: J Nucl Med Date: 2018-04-13 Impact factor: 10.057
Authors: Scott C Morgan; Karen Hoffman; D Andrew Loblaw; Mark K Buyyounouski; Caroline Patton; Daniel Barocas; Soren Bentzen; Michael Chang; Jason Efstathiou; Patrick Greany; Per Halvorsen; Bridget F Koontz; Colleen Lawton; C Marc Leyrer; Daniel Lin; Michael Ray; Howard Sandler Journal: J Clin Oncol Date: 2018-10-11 Impact factor: 44.544
Authors: Nina Natascha Harke; Christian Wagner; Nikolaos Liakos; Katarina Urbanova; Mustapha Addali; Boris A Hadaschik; Jorn H Witt Journal: World J Urol Date: 2020-05-02 Impact factor: 4.226
Authors: Boris Gershman; Paul Maroni; Jon C Tilburt; Robert J Volk; Badrinath Konety; Charles L Bennett; Alexander Kutikov; Marc C Smaldone; Victor Chen; Simon P Kim Journal: World J Urol Date: 2019-01-22 Impact factor: 4.226
Authors: Lars J Petersen; Julie B Nielsen; Niels C Langkilde; Astrid Petersen; Ali Afshar-Oromieh; Nandita M De Souza; Katja De Paepe; Rune V Fisker; Dennis T Arp; Jesper Carl; Uwe Haberkorn; Helle D Zacho Journal: World J Urol Date: 2019-06-12 Impact factor: 4.226
Authors: S Roy; M E Hyndman; B Danielson; A Fairey; R Lee-Ying; W Y Cheung; A R Afzal; Y Xu; T Abedin; H C Quon Journal: Curr Oncol Date: 2019-08-01 Impact factor: 3.677